We and others have evaluated the clinical utility and potential value of measuring CXCL13 in the serum or cerebrospinal fluid (CSF) as a biomarker for MS and other neuroinflammatory conditions [28,29,30,31]. Here, CXCL13 is linked to myeloid sarcoma.